After a very public back-and-forth over COVID-19 vaccine supplies in Europe earlier this year, AstraZeneca said it would aim to deliver 40 million doses in the first quarter. It’s now rolling the estimate back to 30 million, Reuters reports—the same figure that triggered the initial controversy. Meanwhile, in some countries, doses are going unused.